Lubiprostone
- Generic Name
- Lubiprostone
- Brand Names
- Amitiza
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32F2O5
- CAS Number
- 136790-76-6
- Unique Ingredient Identifier
- 7662KG2R6K
- Background
Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften the st...
- Indication
Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain. It is also indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in female patients ≥18 years old.
- Associated Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C), Opioid Induced Constipation (OIC), Chronic idiopathic constipation (CIC)
- Associated Therapies
- -
Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- BioDelivery Sciences International
- Target Recruit Count
- 34532
- Registration Number
- NCT03720613
- Locations
- 🇺🇸
Research Site, Wilmington, Delaware, United States
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 552
- Registration Number
- NCT03097861
- Locations
- 🇺🇸
Investigative Site, Richmond, Virginia, United States
🇺🇸Investigative Sitee, High Point, North Carolina, United States
🇺🇸Investigative Site 2, Jackson, Tennessee, United States
Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 87
- Registration Number
- NCT02766777
- Locations
- 🇺🇸
Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States
🇺🇸Pioneer Clinical Research, Bellevue, Nebraska, United States
🇺🇸Methodist Medical Center, Peoria, Illinois, United States
Lubiprostone for Chronic Idiopathic Constipation Treatment
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 211
- Registration Number
- NCT02729909
Lubiprostone for Treatment of Chronic Idiopathic Constipation
- Conditions
- Interventions
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 156
- Registration Number
- NCT02695719
Lubiprostone for the Treatment of Chronic Idiopathic Constipation
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 204
- Registration Number
- NCT02651155
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT02544152
- Locations
- 🇺🇸
E Squared Research, Inc., Huntsville, Alabama, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Wake Research Associates, LLC, Raleigh, North Carolina, United States
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Braintree Laboratories
- Target Recruit Count
- 459
- Registration Number
- NCT02481947
- Locations
- 🇺🇸
BLI Research Site 12, Artesia, California, United States
🇺🇸BLI Research Site 13, Laguna Hills, California, United States
🇺🇸BLI Research Site 47, Owensboro, Kentucky, United States
Lubiprostone for Children With Constipation
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT02138136
- Locations
- 🇺🇸
Gastrointestinal Associates, PA, Jackson, Mississippi, United States
🇺🇸Children's Hospital of Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Lubiprostone in Children With Functional Constipation
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 606
- Registration Number
- NCT02042183
- Locations
- 🇺🇸
Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.